Hologen AI Commits Up to $430 Million to Advance MeiraGTx’s Parkinson’s Gene Therapy to Phase 3 and Beyond

Hologen AI has pledged up to $430 million through a strategic partnership to support MeiraGTx in advancing its gene therapy for Parkinson’s disease through Phase 3 clinical trials and toward commercialization.
The therapy, known as AAV-GAD, delivers a gene encoding an enzyme that converts glutamate into GABA, a neurotransmitter that plays a critical role in motor dysfunction associated with Parkinson’s disease. In a Phase 2 clinical trial conducted last October, AAV-GAD demonstrated its ability to improve motor control and enhance the quality of life for patients.
Investment and Partnership Structure

Following the therapy’s entry into Phase 3 development, Hologen AI became a key participant in MeiraGTx’s commercialization plans. Under the terms of the agreement:
Hologen AI made an initial payment of $200 million to MeiraGTx.
A joint venture was established, with MeiraGTx holding 30% ownership.
Hologen AI will contribute up to $230 million in additional capital through its newly formed subsidiary, Hologen Neuro AI.
MeiraGTx will oversee clinical supply and manufacturing, leveraging its facilities in New York City, London, and Shannon, Ireland, which feature end-to-end gene therapy production capabilities.
Hologen AI has secured a minority ownership stake in MeiraGTx’s manufacturing operations.
AI-Driven Insights and Clinical Advancements
Hologen AI’s expertise in artificial intelligence has played a crucial role in MeiraGTx’s research strategy. CEO Alexandria Forbes, Ph.D., highlighted how Hologen AI’s AI-driven analysis of brain physiology in 14 patients from the Phase 2 trial has helped mitigate risks associated with the upcoming Phase 3 study.

Expanding Research and Industry Impact
The partnership aligns with growing industry interest in MeiraGTx’s research. Sanofi recently invested $30 million to explore the company’s advancements in immunology, inflammation, central nervous system disorders, and metabolic diseases.
Beyond Parkinson’s, MeiraGTx’s gene therapy platform has shown promise in other areas. Preclinical studies demonstrated its potential to protect motor neurons in amyotrophic lateral sclerosis (ALS) models. Additionally, MeiraGTx’s gene therapy for blindness enabled 11 legally blind newborns to gain improved vision following treatment.
With Hologen AI’s backing, MeiraGTx is well-positioned to advance AAV-GAD and expand the potential of gene therapy in treating neurological disorders.